Mostrando 9 resultados de: 9
Filtros aplicados
Publisher
American Journal of Therapeutics(7)
Archivos Venezolanos de Farmacologia y Terapeutica(1)
International Journal of Molecular Sciences(1)
Área de conocimiento
Medicina interna(4)
Farmacología(3)
Diabetes(2)
Enfermedad cardiovascular(2)
Fisiología(2)
Origen
scopus(9)
An elevated level of physical activity is associated with normal lipoprotein(a) levels in individuals from Maracaibo, Venezuela
ArticleAbstract: Coronary artery disease is the main cause of death worldwide. Lipoprotein(a) [Lp(a)], is an independPalabras claves:Cardiovascular Risk, Lifestyle, lipoprotein(a), Physical activityAutores:Acosta L., Añez-Ramos R., Aparicio D., Arráiz N., Cano R.A., Cano-Ponce C., Colmenares C., Faria J., Finol F., Mengual-Moreno E., Peñaranda L., Pineda C., Rodriguez D., Rojas E.R., Rojas-Quintero J., Sanchez W., Sorell L.T., Toledo A.C., Urribarí J., Valmore Bermúdez, Velasco M.Fuentes:scopusEffect of cigarette smoking on the oxidant/antioxidant balance in healthy subjects
Conference ObjectAbstract: BACKGROUND AND PURPOSE: Cigarette smoking has been associated with the development of cardiovascularPalabras claves:Ascorbic acid, Cigarette smoking, Glutathione, Malondialdehyde, Nitric oxide, Vitamin CAutores:Amell A., Cano R.A., Cano-Ponce C., Chávez J., Ciszek A., Contreras F., Hernández-Hernandez R., Israili Z.H., Medina M.T., Reyna-Villasmil N., Souki-Rincón A., Suárez G., Toledo A., Valasco M., Valmore Bermúdez, Vargas M.E.Fuentes:scopusEffect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects
ArticleAbstract: Dopamine agonists play an important role in the regulation of the central nervous-cardiovascular, rePalabras claves:dopamine, Dopaminergic agonists, Dopaminergic receptors, Hypertension, Insulin, Type 2 Diabetes mellitusAutores:Bolívar H., Cano R.A., Contreras F., Foullioux C., Lares M., Leal E.M., Maroun C., Pacheco B., Valmore Bermúdez, Velasco M.Fuentes:scopusEffects of metoclopramide and metoclopramide/dopamine on blood pressure and insulin release in normotensive, hypertensive, and type 2 diabetic subjects
ArticleAbstract: The objective is to determine cardiovascular and insulin release effects under metoclopramide (MTC)Palabras claves:dopamine, Dopamine receptors, Hypertension, Insulin release, Metoclopramide, Type 2 DiabetesAutores:Bolívar H., Cano R.A., Contreras F., Fouillioux C., González M.C., Hernández-Hernandez R., Lares M., Valmore Bermúdez, Velasco M.Fuentes:scopusInsulin resistance and hyperinsulinemia as risk factors for cardiovascular disease
Conference ObjectAbstract: Insulin resistance is defined as a metabolic state in which insulin peripheral effects are diminishePalabras claves:Cardiovascular disease, Hiperinsulinemia, Insulin, Insulin ResistanceAutores:Acosta L., Aparicio D., Arráiz N., Canelón R., Cano R.A., Deisiree S., Finol F., Leal E.M., Linares S., Luti Y., Rojas E.R., Rojas-Quintero J., Valmore BermúdezFuentes:scopusMetformin plus low-dose glimeperide significantly improves homeostasis model assessment for insulin resistance (HOMA<inf>IR</inf>) and β-cell function (HOMA<inf>β-cell</inf>) without hyperinsulinemia in patients with type 2 diabetes mellitus
Conference ObjectAbstract: OBJECTIVE: Type 2 diabetes mellitus is characterized by insulin resistance and defects in insulin sePalabras claves:Glimeperide, HOMA, Homeostasis model assessment, Insulin Resistance, Metformin, Type 2 Diabetes mellitus, β-cell functionAutores:Bermúdez-Arias F., Cano R.A., Cano-Ponce C., Ciscek A., Contreras F., Hernández-Hernandez R., Israili Z.H., Leal E.M., Lemus M.A., Medina M.T., Seyfi H.A., Souki-Rincón A., Valasco M., Valmore BermúdezFuentes:scopusPharmacologic management of isolated low high-density lipoprotein syndrome
ArticleAbstract: High-density lipoprotein (HDL) cholesterol is a heterogeneous group of lipoproteins exhibiting a varPalabras claves:atherosclerosis, cholesterol, Coronary artery disease, dyslipidemia, HDLc, Reverse cholesterol transportAutores:Acosta L., Amell A., Arráiz N., Bermúdez F.A., Cano R.A., Cano-Ponce C., Finol F., Hernández-Hernandez R., Hidalgo J., Kendall P., Manuel V., Pabón M.R., Reyna-Villasmil N., Valmore BermúdezFuentes:scopusLipoprotein(a): From molecules to therapeutics
ReviewAbstract: Lipoprotein (a) [Lp(a)] was discovered by Kare Berg in 1963 from the study of low-density lipoproteiPalabras claves:Atherogenesis, Cardiovascular disease, Hyperlipoproteinemia(a), lipoprotein(a), therapeuticsAutores:Amell A., Aparicio D., Arráiz N., Cabrera M., Canelón R., Cano R.A., Cano-Ponce C., Faria J., Gotera D., Guerra-Torres X.E., Mengual-Moreno E., Reyna-Villasmil N., Rojas E.R., Sorell L.T., Valmore Bermúdez, Velasco M.Fuentes:scopusRole of endocrine-disrupting chemicals in the pathogenesis of non-alcoholic fatty liver disease: A comprehensive review
ReviewAbstract: Non-alcoholic fatty liver disease (NAFLD) is considered the most common liver disorder, affecting arPalabras claves:Endocrine-disrupting chemicals, Environmental pollutants, Exposure, Liver disorder, Non-alcoholic fatty liver diseaseAutores:Cano G., Cano R.A., Dávila L.C.A., Diaz M.P., Gomez Y., González M.C., Manzano A., Ortega A., Parra H., Pérez J.L., Rojas-Quintero J., Valero-Cedeño N.J., Valmore Bermúdez, Veliz T.Fuentes:scopus